Bhave Varun M, Lamba Nayan, Tjong Michael C, Aizer Ayal A, Bi Wenya Linda
Harvard Medical School, Boston , Massachusetts , USA.
Harvard Radiation Oncology Program, Harvard University, Boston , Massachusetts , USA.
Neurosurgery. 2024 Jan 1;94(1):117-128. doi: 10.1227/neu.0000000000002626. Epub 2023 Jul 25.
Although stereotactic radiation has frequently supplanted whole-brain radiation therapy (WBRT) in treating patients with multiple brain metastases, the role of surgery for these patients remains unresolved. No randomized trials have compared surgical resection with postoperative stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT) to SRS/SRT alone. Previous studies addressing surgery for patients with multiple brain metastases are often limited by small sample sizes, a lack of appropriate comparison groups, or a focus on patients treated before recent advances in targeted therapy and immunotherapy. We compared outcomes in patients with multiple brain metastases treated with surgical resection and postoperative SRS/SRT to those treated with SRS/SRT alone.
We studied 734 patients with multiple newly diagnosed brain metastases (surgery with SRS/SRT, n = 228; SRS/SRT alone, n = 506) from 2011 to 2022 in a retrospective, single-institution cohort. Patients who received upfront whole-brain radiotherapy were excluded. Cox proportional hazards models were constructed for overall survival and additional intracranial outcomes.
After adjustment for potential confounders, surgery with postoperative SRS/SRT was associated with decreased all-cause mortality compared with SRS/SRT alone (hazard ratio [HR]: 0.67, 95% CI [0.50-0.89], P = 5.56 × 10 -3 ). The association between surgical resection and overall survival was replicated in a subset of the cohort after cardinality matching (HR: 0.64, 95% CI [0.46-0.88], P = 6.68 × 10 -3 ). Patients with melanoma benefited significantly less from surgical resection compared with patients with other tumor types, most notably non-small-cell lung cancer. Compared with definitive SRS/SRT, cavity SRS/SRT was associated with a significantly reduced risk of both symptomatic radiation necrosis (HR: 0.22, 95% CI [0.08-0.59], P = 2.70 × 10 -3 ) and radiographic radiation necrosis (HR: 0.23, 95% CI [0.09-0.57], P = 1.43 × 10 -3 ) in multivariable models.
In patients with multiple brain metastases, surgical resection before SRS/SRT is associated with reduced mortality and radiation necrosis. Prospective studies may further delineate patient populations that benefit from aggressive local, brain-directed treatment even with significant intracranial disease burden.
尽管立体定向放射治疗在治疗多发性脑转移瘤患者时已常取代全脑放射治疗(WBRT),但手术对这些患者的作用仍未明确。尚无随机试验比较手术切除联合术后立体定向放射外科治疗(SRS)或立体定向放射治疗(SRT)与单纯SRS/SRT治疗的效果。以往针对多发性脑转移瘤患者手术治疗的研究往往受限于样本量小、缺乏合适的对照组,或侧重于靶向治疗和免疫治疗取得最新进展之前接受治疗的患者。我们比较了接受手术切除联合术后SRS/SRT治疗的多发性脑转移瘤患者与单纯接受SRS/SRT治疗的患者的预后。
我们对2011年至2022年在单机构队列中确诊的734例多发性新发性脑转移瘤患者进行了回顾性研究(手术联合SRS/SRT治疗,n = 228;单纯SRS/SRT治疗,n = 506)。排除接受初始全脑放疗的患者。构建Cox比例风险模型以评估总生存期和其他颅内结局。
在对潜在混杂因素进行调整后,与单纯SRS/SRT治疗相比,手术联合术后SRS/SRT治疗与全因死亡率降低相关(风险比[HR]:0.67,95%置信区间[CI][0.50 - 0.89],P = 5.56×10⁻³)。在基数匹配后的队列子集中,手术切除与总生存期之间的关联得到了重复验证(HR:0.64,95% CI[0.46 - 0.88],P = 6.68×10⁻³)。与其他肿瘤类型患者相比,黑色素瘤患者从手术切除中获益明显较少,最显著的是非小细胞肺癌患者。在多变量模型中,与确定性SRS/SRT相比,空洞SRS/SRT与有症状放射性坏死(HR:0.22,95% CI[0.08 - 0.59],P = 2.70×10⁻³)和影像学放射性坏死(HR:0.23,95% CI[0.09 - 0.57],P = 1.43×10⁻³)的风险显著降低相关。
在多发性脑转移瘤患者中,SRS/SRT治疗前进行手术切除与死亡率降低和放射性坏死减少相关。前瞻性研究可能会进一步明确即使颅内疾病负担较重但仍能从积极的局部脑定向治疗中获益的患者群体。